Benzinga’s Biggest Losers (HLCS, CYCC, SNSS, AMED, APKT)
December 16, 2009 1:01 PM
Helicos BioSciences Corp. (NASDAQ: HLCS)(FREE stock trend analysis) has plunged 30.51% to $0.952 on 5.31 million shares after Helicos BioSciences announced that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit. So far this year, HLCS is up over 144%.
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)(FREE stock trend analysis) fell 17.74% to $1.02 on 1.01 million shares after Cyclacel announced that it commenced a public offering of 3,863,050 of its ordinary shares. So far this year, CYCC is up over 145%.
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)(FREE stock trend analysis) is trading lower by 16% to $1.47. So far in the last five trading sessions, shares of SNSS have moved up over 146%.
Amedisys, Inc. (NASDAQ: AMED)(FREE stock trend analysis) shares are down 5.37% to $44.42. The 52-week trading range for AMED is $25.20 - $53.30. In the last six months, Amedisys surged over 50%.
Acme Packet, Inc. (NASDAQ: APKT)(FREE stock trend analysis) fell 7.81% to $10.98 on 1.99 shares. The 52-week trading range for APKT is $3.11 - $12.25. In the last six months, Acme surged over 108%.
